What is HC Wainwright’s Estimate for ACHV Q1 Earnings?

Achieve Life Sciences, Inc. (NASDAQ:ACHV) – Equities researchers at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Achieve Life Sciences in a research report issued on Wednesday, March 25th. HC Wainwright analyst B. Folkes expects that the biopharmaceutical company will post earnings per share of ($0.30) for the quarter. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Achieve Life Sciences’ Q2 2026 earnings at ($0.33) EPS, Q3 2026 earnings at ($0.32) EPS and Q4 2026 earnings at ($0.33) EPS.

Achieve Life Sciences (NASDAQ:ACHV) last posted its quarterly earnings results on Tuesday, March 24th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.01).

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Achieve Life Sciences in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Achieve Life Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.50.

Achieve Life Sciences Stock Performance

Achieve Life Sciences stock opened at $2.89 on Thursday. The company has a market cap of $153.83 million, a PE ratio of -2.22 and a beta of 1.81. The company has a fifty day moving average price of $4.38 and a two-hundred day moving average price of $4.29. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.39 and a quick ratio of 5.14. Achieve Life Sciences has a 12 month low of $1.84 and a 12 month high of $6.03.

Hedge Funds Weigh In On Achieve Life Sciences

Several institutional investors have recently made changes to their positions in the stock. Franklin Resources Inc. grew its holdings in shares of Achieve Life Sciences by 81.3% during the second quarter. Franklin Resources Inc. now owns 4,459,014 shares of the biopharmaceutical company’s stock valued at $10,077,000 after purchasing an additional 2,000,079 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Achieve Life Sciences by 14.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,461,802 shares of the biopharmaceutical company’s stock worth $7,755,000 after purchasing an additional 311,925 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Achieve Life Sciences by 472.3% in the 4th quarter. Millennium Management LLC now owns 1,359,116 shares of the biopharmaceutical company’s stock worth $6,755,000 after purchasing an additional 1,121,614 shares during the last quarter. Hudson Bay Capital Management LP acquired a new position in Achieve Life Sciences during the 2nd quarter valued at approximately $2,652,000. Finally, Marshall Wace LLP grew its stake in Achieve Life Sciences by 31.5% during the 4th quarter. Marshall Wace LLP now owns 1,019,281 shares of the biopharmaceutical company’s stock worth $5,066,000 after buying an additional 244,428 shares during the last quarter. 33.52% of the stock is owned by institutional investors.

Trending Headlines about Achieve Life Sciences

Here are the key news stories impacting Achieve Life Sciences this week:

• Positive Sentiment: FDA PDUFA set for June 20, 2026 for cytisinicline; company exceeded long‑term safety requirements and secured manufacturing capacity, supporting a potential commercial launch in 1H 2027 if approved. This is the primary near‑term upside catalyst. Achieve Life Sciences: Maintaining ‘Buy’ On Upcoming PDUFA And Expansion Into Vaping Cessation
• Positive Sentiment: Company plans to start the Phase 3 ORCA‑V2 trial for vaping cessation in 1H 2026, expanding the addressable market beyond smoking cessation and adding a second commercialization opportunity. Achieve Life Sciences: Maintaining ‘Buy’ On Upcoming PDUFA And Expansion Into Vaping Cessation
• Positive Sentiment: New publication links cytisinicline’s receptor selectivity to low nausea and favorable tolerability — supportive safety/tolerability data can improve prescribing uptake and payer discussions if approved. Achieve Life Sciences Announces Publication in Nicotine & Tobacco Research
• Positive Sentiment: Unusually large purchases of call options indicate speculative/bullish positioning ahead of the PDUFA and other catalysts, often amplifying upward price moves on positive headlines. Investors Purchase Large Volume of Call Options on Achieve Life Sciences (NASDAQ:ACHV)
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and maintained a $12 price target (wide upside vs. current levels), and published EPS/quarterly loss forecasts — analyst support lends conviction to the bullish thesis. HC Wainwright buy rating / $12 target (Benzinga)
• Neutral Sentiment: Q4 2025 earnings call summary was published (earnings have been negative historically and management commentary may reiterate runway/milestones) — useful for context but not a new catalytic change versus the regulatory timeline. Achieve Life Sciences, Inc. Q4 2025 Earnings Call Summary

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.